您当前的位置:
Fumalic acid. (Synonyms: 阿魏酸; Coniferic acid)
目录号: PC13540 纯度: ≥98%
CAS No. :1135-24-6
商品编号 规格 价格 会员价 是否有货 数量
PC13540-20mg 20mg ¥128.00 请登录
PC13540-50mg 50mg ¥392.00 请登录
PC13540-10mM (in 1mL DMSO) 10mM (in 1mL DMSO) ¥784.00 请登录
Medlife所售产品仅用于科学研究(非临床研究),非药品不可食用,不可用于人体或动物的临床诊断和治疗,我们不为个人提供产品及服务。产品COA等资料,可至下方“质量控制”中下载。
中文名称
Fumalic acid.
中文别名
阿魏酸;3-(4-羟基-3-甲氧基苯基)-2-丙烯酸;3-(4-羟基-3-甲氧基苯基)2-丙烯酸;4-羟基-3-甲氧基肉桂酸;3-甲氧基-4-羟基桂皮酸;4-羟基3-甲氧基肉桂酸;咖啡酸-3-甲醚;4-羟基-3-甲氧基桂皮酸;3-甲氧基-4-羟基肉桂酸;4-氰基-6-氟吲哚;阿莫西林克拉维酸钾;阿魏酸 对照品标准品;阿魏酸 USP标准品;阿魏酸 标准品;阿魏酸(合成);阿魏酸(天然);阿魏酸,BR;阿魏酸,CP;阿魏酸,植物提取物,标准品,对照品;阿魏酸 分析对照品;阿魏酸对照品;阿魏酸钠;安五脂素;合成阿魏酸;天然阿魏酸;(E)-阿魏酸;4-羟基-3-甲氯基肉桂酸;4-羟基-3-甲氧基肉桂酸,咖啡酸-3-甲醚;食品防腐剂;顺式阿魏酸;有机中间体;阿魏酸天然
英文名称
Fumalic acid
英文别名
4-Hydroxy-3-methoxycinnamic acid;Ferulic acid;Forulic acid;(2E)-3-(4-Hydroxy-3-methoxyphenyl)acrylic acid;4-Hydroxy-3-Methoxycinnamic Acid,mixture of cis and trans;Ferulic acid;4-hydroxy-3-methoxy-cinnamic acid;conifericacid;ferulaic acid;FERULIC ACID pure;Ferulic acid,matrix substance for MALDI-MS;Ferulic?acid;FERULLIC ACID;Fumalic acid;WAKO068-04821;3-Methoxy-4-hydroxy-cinnamic acid;3-(4-Hydroxy-3-methoxyphenyl)acrylic acid;orulic acid;trans-Ferulic Acid;trans-4-Hydroxy-3-methoxycinnamic acid;(E)-Ferulic acid;ferulate;Coniferic acid;2-Propenoic acid, 3-(4-hydroxy-3-methoxyphenyl)-;Ferulic acid, trans-;(2E)-3-(4-hydroxy-3-methoxyphenyl)prop-2-enoic acid;3-(4-Hydroxy-3-methoxyphenyl)-2-propenoic acid;Cinnamic acid, 4-hydroxy-3-methoxy-;3-methoxy-4-hydroxycinnamic acid;(E)-3-(4-Hydroxy-3-methoxyphenyl)-2-propeno
Cas No.
1135-24-6
分子式
C10H10O4
分子量
194.18
包装储存
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
生物活性

Ferulic acid is a novel fibroblast growth factor receptor 1 (FGFR1) inhibitor with IC50s of 3.78 and 12.5 μM for FGFR1 and FGFR2, respectively.

性状

Solid

IC50 & Target[1][2]

FGFR1

3.78 μM (IC50)

FGFR2

12.5 μM (IC50)

Human Endogenous Metabolite

 

体外研究(In Vitro)

Ferulic acid (FA) is a novel fibroblast growth factor receptor 1 (FGFR1) inhibitor with IC50s of 3.78 and 12.5 μM for FGFR1 and FGFR2, respectively. Ferulic acid exhibits great inhibitory activity on FGFR1 with an inhibitory rate of 92% at 1 μM. The proliferation of HUVEC stimulated by FGF1 is markedly decreased after Ferulic acid treatment ranging from 5 to 40 μM for 24 h. Ferulic acid does not exert significant cell viability up to 20 μM, but over 30 μM Ferulic acid exhibits a cytotoxic effect in HUVEC compare to the control. Ferulic acid inhibits FGF1-induced HUVEC migration and invasion in a dose-dependent manner. Ferulic acid markedly suppresses the FGF1-induced phosphorylation of PI3K and Akt. Ferulic acid treatments significantly inhibit MMP-2 and MMP-9 expression stimulated by FGF1.

Medlife has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究(In Vivo)

Treatment with Ferulic acid (FA) potently inhibits FGF1-induced neovascularization. It is found that intragastric administration of Ferulic acid markedly inhibits tumor volume and tumor weight, as compare to the counterparts treated with DMSO. Furthermore, Ferulic acid treatment is well tolerated, and there is no significant difference in weight between the vehicle group and the FA-treated groups. Ferulic acid (0.01, 0.1, 1 or 10 mg/kg) given by oral route decreases significantly the immobility time in the forced swimming test (FST) and tail suspension test (TST), whereas produces no effect in the open-field test. Results demonstrate that the administration of Ferulic acid (0.001 mg/kg, p.o.) boosts the antidepressant-like effect of fluoxetine (5 mg/kg, p.o.) in the TST.

Medlife has not independently confirmed the accuracy of these methods. They are for reference only.

运输条件

Room temperature or refrigerated transportation.

储存方式
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
ClinicalTrial
结构分类
来源
参考文献
溶解度数据
体外研究: 

DMSO : 100 mg/mL (514.99 mM; Need ultrasonic)

配制储备溶液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 5.1499 mL 25.7493 mL 51.4986 mL
5 mM 1.0300 mL 5.1499 mL 10.2997 mL
10 mM 0.5150 mL 2.5749 mL 5.1499 mL
*

产品不同,其溶解度不同。建议根据产品选择合适的溶剂配制储备溶液;配成溶液后,建议分装保存,避免反复冻融造成的产品失效
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month。-80°C 储存时,建议在 6 个月内使用,-20°C 储存时,建议在 1 个月内使用。

体内研究:

建议根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都建议先按照 体外研究 方式配制澄清的储备液,再依次添加助溶剂:

——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用; 以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶

  • 1.

    建议依照次序添加每种溶剂: 10% DMSO    40% PEG300    5% Tween-80    45% saline

    Solubility: ≥ 2.5 mg/mL (12.87 mM); Clear solution

    此方案可获得 ≥ 2.5 mg/mL (12.87 mM,饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀;向上述体系中加入50 μL Tween-80,混合均匀;然后继续加入 450 μL生理盐水定容至 1 mL。

    将 0.9 g 氯化钠,完全溶解于 100 mL ddH?O 中,得到澄清透明的生理盐水溶液
  • 2.

    建议依照次序添加每种溶剂: 10% DMSO    90% (20% SBE-β-CD in saline)

    Solubility: ≥ 2.5 mg/mL (12.87 mM); Clear solution

    此方案可获得 ≥ 2.5 mg/mL (12.87 mM,饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中,混合均匀。

    将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中,再用生理盐水定容至 10 mL,完全溶解,澄清透明
  • 3.

    建议依照次序添加每种溶剂: 10% DMSO    90% corn oil

    Solubility: ≥ 2.5 mg/mL (12.87 mM); Clear solution

    此方案可获得 ≥ 2.5 mg/mL (12.87 mM,饱和度未知) 的澄清溶液,此方案不适用于实验周期在半个月以上的实验。

    以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中,混合均匀。

*
搜索质检报告(COA)

1:一般建议:溶解度为Medlife测试数据,可能与文献描述存在差异。这是由于生产工艺和批次不同产生的正常现象。为了使其更好的溶解,请用37℃加热试管并在超声波水浴中震动片刻。不同批次产品溶解度各有差异,仅做参考,具体以实验方案为准。

2:储存条件:粉末-20°C一般情况可以保存3年,溶于溶剂-80°C一般情况可以保存1年。不同产品及不同批次产品可能存在差异,请细致阅读产品信息,并辅助参考相关文献描述。

The molarity calculator equation
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
The dilution calculator equation
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2